Novel therapeutic strategies for patients with metastatic triple-negative breast cancer

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer

Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and...

Full description

Bibliographic Details
Main Authors:	Inna P. Ganshina, Olga O. Gordeeva, Mariam Sh. Manukian
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2021-02-01
Series:	Современная онкология
Subjects:	triple negative breast cancer chemotherapy antiangiogenic therapy immunotherapy parp inhibitors drug therapy
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/61149/44238

Similar Items

Opportunities for metastatic triple negative breast cancer therapy
by: Inna P. Ganshina, et al.
Published: (2021-05-01)

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
by: Anna Diana, et al.
Published: (2020-03-01)

A review of current progress in triple-negative breast cancer therapy
by: Shen Meiying, et al.
Published: (2020-11-01)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
by: Claire H. Li, et al.
Published: (2019-12-01)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
by: Dey Nandini, et al.
Published: (2021-05-01)

Therapeutic methods in the treatment of triple-negative breast cancer - a review
by: Karolina Joanna Ziętara, et al.
Published: (2022-07-01)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
by: Mariya Yordanova, et al.
Published: (2021-12-01)

Immunotherapeutic interventions of Triple Negative Breast Cancer
by: Zehuan Li, et al.
Published: (2018-05-01)

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
by: Giovanna Garufi, et al.
Published: (2022-08-01)

Recent advances in therapeutic strategies for triple-negative breast cancer
by: Yun Li, et al.
Published: (2022-08-01)

Diagnostics and systemic treatment of triple-negative breast cancer: discoveries of the past, challenges for the future
by: Grzegorz Chmielewski, et al.
Published: (2024-03-01)

Clinical Trials and Current Progress in the Treatment of Triple-negative Breast Cancer
by: LI Linrong, et al.
Published: (2023-01-01)

The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
by: Olga O Gordeeva, et al.
Published: (2019-09-01)

Predictors of Complete Pathological Response with Chemoimmunotherapy in Triple-Negative Breast Cancer: A Meta-Analysis
by: Arya Mariam Roy, et al.
Published: (2023-12-01)

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
by: Roberta Caputo, et al.
Published: (2023-08-01)

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
by: Shuanghe Li, et al.
Published: (2022-10-01)

Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway
by: Ting Yang, et al.
Published: (2021-04-01)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
by: Giacomo Barchiesi, et al.
Published: (2021-11-01)

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
by: Domiziana Masci, et al.
Published: (2023-11-01)

Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
by: Tong L, et al.
Published: (2023-08-01)

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
by: Yaxin Liu, et al.
Published: (2023-09-01)

Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions
by: Laura Morrison, et al.
Published: (2023-07-01)

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer
by: Alyssa Vito, et al.
Published: (2021-05-01)

Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
by: Onyinyechi Obidiro, et al.
Published: (2023-06-01)

Recent advances in targeted strategies for triple-negative breast cancer
by: Shuangli Zhu, et al.
Published: (2023-08-01)

Triple negative breast cancer: special histological types and emerging therapeutic methods
by: Lu Cao, et al.
Published: (2020-05-01)

Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning
by: Lijuan Tang, et al.
Published: (2023-06-01)

Research Progress on Immunization and Targeted Therapy for Triple-negative Breast Cancer
by: SHI Chao, et al.
Published: (2023-07-01)

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer
by: Paige Baldwin, et al.
Published: (2024-03-01)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
by: Aiswarya Chaudhuri, et al.
Published: (2022-04-01)

Advances in the Management of Early-Stage Triple-Negative Breast Cancer
by: Prarthna V. Bhardwaj, et al.
Published: (2023-08-01)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
by: Xinyang Li, et al.
Published: (2022-02-01)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
by: Jakub Wesolowski, et al.
Published: (2022-08-01)

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
by: Silvia Mezi, et al.
Published: (2021-03-01)

New research advances and future prospect in precision treatment of triple-negative breast cancer
by: XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin
Published: (2022-08-01)

Therapy options for metastatic triple negative breast cancer
by: E. V. Glazkova, et al.
Published: (2022-06-01)

New chemotherapy options for triple-negative breast cancer (review of literature)
by: M A Sekundova, et al.
Published: (2014-03-01)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Xu Liu, et al.
Published: (2021-10-01)

Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
by: Filomena Marino Carvalho
Published: (2023-11-01)

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
by: Andras G. Lacko, et al.
Published: (2013-06-01)